TriSalus Life Sciences (NASDAQ:TLSIW) Trading 9.9% Higher – Here’s Why

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) rose 9.9% during mid-day trading on Thursday . The stock traded as high as $1.56 and last traded at $1.56. Approximately 9,633 shares traded hands during mid-day trading, an increase of 14% from the average daily volume of 8,458 shares. The stock had previously closed at $1.42.

TriSalus Life Sciences Price Performance

The company has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $1.51.

Institutional Trading of TriSalus Life Sciences

A hedge fund recently raised its stake in TriSalus Life Sciences stock. Citadel Advisors LLC lifted its holdings in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) by 439.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 126,876 shares of the company’s stock after buying an additional 103,336 shares during the period. Citadel Advisors LLC’s holdings in TriSalus Life Sciences were worth $199,000 at the end of the most recent quarter.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.